TGNA:FRA
Transgene SA
€ ०.६७
arrow_downward
-०.१५%(-०.००१००) 1D
अक्टोबर १५, ०८:०३:१८ GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€ ०.६७
High
€ ०.६७
Low
€ ०.६७
Mkt. cap
१९.२५ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.४८
52-wk low
€ ०.६०
EPS
-€ ०.१७
No. of employees
१५२
Open
€ ०.६७
High
€ ०.६७
Low
€ ०.६७
Mkt. cap
१९.२५ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.४८
52-wk low
€ ०.६०
EPS
-€ ०.१७
No. of employees
१५२
News stories
From web sources and news partners
Simply Wall Street
·
४२ मिनेट पहिले
Why Pegasystems Fell Even As Sales Rose
Benzinga
·
४९ मिनेट पहिले
RedCloud Holdings Shares Rise 18.40% After Hours - RedCloud Holdings (NASDAQ:RCT)
Stocktwits
·
४ घण्टा पहिले
SKHY Tracks Worst Month Since Nasdaq Debut: SK Hynix Reportedly Wants To Ship More Chip Tools To China Before Building In US
Investor's Business Daily
·
५ घण्टा पहिले
Tech Futures Fall; Anthropic Revenue Jumps, But Not Enough?
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA